RxDoctor Payments Data

Lauren Byrne, MD

Urology · Chandler, AZNPI 1265588859

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,489 of the $11,852 with a category attached, or 71.6%. 43 manufacturers reported payments, led by Caldera Medical, Inc at 24.9% of the total.

$11,852in general payments, 2019–2025

Across 397 payments — averaging $29.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Caldera Medical, Inc$3K
  • Valencia Technologies Corporation$1K
  • Teleflex LLC$1K
  • Coloplast$960
  • Boston Scientific$573
  • Femselect Inc.$455
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$8007%
  • Travel & lodging$1,58113%
  • Food & beverage$8,48972%
  • Education$1771%
  • Gifts$8057%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,852 in reported general payments places this provider in the 80th percentile of 269 urology providers in Arizona.

See all urology providers in Arizona

Medicare billing

Part B allowed, 2024
$557,791
Medicare patients
786
Services billed
8,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron422$342,679
MyrbetriqMirabegron243$222,504
BotoxOnabotulinumtoxina17$10,959
Mirabegron ErMirabegron13$10,574
Alfuzosin Hcl ErAlfuzosin Hcl278$7,082
Dutasteride138$4,662
Estradiol33$2,799
Tamsulosin Hcl81$847
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst55$743
Testosterone Cypionate33$639
Finasteride28$396
CefuroximeCefuroxime Axetil45$377
Levofloxacin85$247
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim65$180
NitrofurantoinNitrofurantoin Macrocrystal13$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$313$342,679422 claims
Astellas Pharma US IncMyrbetriq$440$222,504243 claims
AbbVieBotox$439$10,95917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 269 urology providers in Arizona.

Other urology in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →